SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

May 18, 2015 07:00 ET

CTD Holdings Names Dr. Benny Liu, M.D. to Scientific Advisory Board

Dr. Liu Is a Leader in the Development of NPC Treatments With Cyclodextrin in Animal Disease Models

ALACHUA, FL--(Marketwired - May 18, 2015) - CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, including the orphan drug designated Trappsol® Cyclo™, today announced the appointment of Dr. Benny Liu, M.D. to the company's Scientific Advisory Board.

Dr. Liu is a widely published and recognized leader in the field of cholesterol metabolism and lysosomal storage diseases. He published the first definitive work showing, in an animal model, the benefits of cyclodextrins in treating Niemann-Pick Type C (NPC), a rare and fatal childhood disease resulting from a genetic mutation in a gene responsible for proper cholesterol metabolism.

Dr. Liu joins Professor James Hildreth, Dr. Caroline Hastings, and Dr. Sharon Hrynkow on the Scientific Advisory Board.

Dr. Hrynkow, who is guiding the CTD international clinical program in her Scientific Advisory Board role, said: "Dr. Liu's insights on the Scientific Advisory Board will be critical to CTD as it works to bring its Trappsol® Cyclo™ orphan drug product into the regulatory arena."

"Dr. Liu's work is well known at CTD and globally," said company President and Chief Executive Officer Dr. Jeffrey Tate. "His pioneering work has paved the way for the cyclodextrin/NPC field, and we look forward to collaborating with him on our international clinical program with the goal of helping NPC patients and their families."

"I am excited and honored to join the Scientific Advisory Board of CTD Holdings. I look forward to working with its members and CTD to advance the development of cyclodextrin for the treatment of Niemann-Pick Type C disease," Dr. Liu said.

Dr. Liu is the Associate Division Chief of Gastroenterology and Hepatology at Alameda County Medical Center, Highland General Hospital. He also is Assistant Clinical Professor at the University of California San Francisco and previously an Assistant Instructor at the University of Texas Southwestern.

His work has been supported by the National Institutes of Health, the Ara Parseghisan Medical Research Foundation and others. Dr. Liu also advises physician principal investigators preparing investigational new drug protocols for the treatment of NPC in humans with cyclodextrin infusions and injections.

About the Company:
CTD Holdings, Inc. is a family of biotechnology growth companies based on cyclodextrin chemistry. Its individual divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in research, pharmaceutical, medical device, cosmetics and nutrition markets. Sphingo Biotechnology, Inc. is developing Trappsol® Cyclo™, an orphan drug designated product, for the treatment of Niemann Pick Type C, a rare and fatal genetic disease in young children. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of ultra-pure cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. CTD, Inc. supplies cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. The companies offer a wide variety of cyclodextrin related manufacturing services to worldwide customers, including custom formulation, manufacturing, and commercial scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's websites: and

Safe Harbor Statement:
This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical grade products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information